Can-Fite BioPharma Ltd. announced the exercise of outstanding warrants for approximately $4.0 million in gross proceeds on September 2, 2026. The company issued 1,591,738 American Depositary Shares (ADSs) at a reduced exercise price of $2.50 per ADS, down from the original $5.00 strike price. In exchange for this cash injection, Can-Fite issued new unregistered warrants to purchase up to 3,183,476 additional ADSs, also exercisable at $2.50 per share until September 2028. H.C. Wainwright & Co. served as the exclusive placement agent for the transaction. The net proceeds are intended to fund research and development, clinical trials, and general corporate purposes. Can-Fite BioPharma Ltd. is a clinical-stage biotechnology company developing proprietary small molecule drugs targeting oncological and inflammatory diseases.
